Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel

Abstract Clinical trials have demonstrated the efficacy and safety of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM); however, prospective real‐world data are limited. This real‐world, prospective, observational study evaluated carfilzomib use, effectiveness and safety in a...

詳細記述

書誌詳細

出版年:	eJHaem
主要な著者:	Xavier Leleu, Eirini Katodritou, Thomas Kuehr, Evangelos Terpos, Jo Caers, Renato Zambello, Alessandra Brescianini, Tony Liang, Sally Wetten, Sorina N. Badelita
フォーマット:	論文
言語:	英語
出版事項:	Wiley 2023-02-01
主題:	carfilzomib multiple myeloma proteasome inhibitor real world relapsed/refractory
オンライン･アクセス:	https://doi.org/10.1002/jha2.595